The company also this year has purchased Vynamic and Cambridge BioMarketing.
The coming digital revolution will change a lot of things, but I guarantee this: It won't replace the importance of the patient-physician relationship.
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy
Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe
J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader
GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus
Pure Communications CEO Andrea Johnston will lead the combined agency.
Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
Teva acquires sensor-based inhaler; EU conditionally approves Amgen's cancer drug, Blincyto; Novartis CEO says targeted therapies may reduce unnecessary US healthcare spending
Walgreens Boots Alliance's global comms team works hand in hand to balance the complexities of a merger and create a unified strategy to inspire all stakeholders.
CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP
The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information
Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014
Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US
Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe
Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend
Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed
Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker